Trial Profile

A Phase 2 Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 14 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cabozantinib (Primary) ; Nivolumab (Primary)
Indications Adenocarcinoma; Prostate cancer
Focus Therapeutic Use
Acronyms CANOPY

Most Recent Events

26 Mar 2025 Planned number of patients changed from 50 to 47.
02 Jul 2024 Planned End Date changed from 12 Oct 2024 to 12 Apr 2027.
02 Jul 2024 Planned primary completion date changed from 12 May 2024 to 12 Apr 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com